On September 25, 2017, Lannett Company received FDA approval for a generic drug indicated by ANDA207333, positioning the company for potential market capture despite unspecified substance details. This clearance allows Lannett to diversify its revenue base, adding another entry to its portfolio as the company continues to target specific niches within a competitive pricing landscape.